CN1731997A - 使用包含选择性细胞因子抑制药物的组合物治疗和控制黄斑变性的方法 - Google Patents

使用包含选择性细胞因子抑制药物的组合物治疗和控制黄斑变性的方法 Download PDF

Info

Publication number
CN1731997A
CN1731997A CNA2003801080906A CN200380108090A CN1731997A CN 1731997 A CN1731997 A CN 1731997A CN A2003801080906 A CNA2003801080906 A CN A2003801080906A CN 200380108090 A CN200380108090 A CN 200380108090A CN 1731997 A CN1731997 A CN 1731997A
Authority
CN
China
Prior art keywords
alkyl
carbon atom
group
phenyl
selective cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801080906A
Other languages
English (en)
Chinese (zh)
Inventor
J·B·泽尔迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN1731997A publication Critical patent/CN1731997A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2003801080906A 2002-10-31 2003-10-31 使用包含选择性细胞因子抑制药物的组合物治疗和控制黄斑变性的方法 Pending CN1731997A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42290002P 2002-10-31 2002-10-31
US60/422,900 2002-10-31

Publications (1)

Publication Number Publication Date
CN1731997A true CN1731997A (zh) 2006-02-08

Family

ID=32312567

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801080906A Pending CN1731997A (zh) 2002-10-31 2003-10-31 使用包含选择性细胞因子抑制药物的组合物治疗和控制黄斑变性的方法

Country Status (12)

Country Link
EP (1) EP1567148A4 (https=)
JP (1) JP2006509743A (https=)
KR (1) KR20050062649A (https=)
CN (1) CN1731997A (https=)
AU (1) AU2003285107B2 (https=)
BR (1) BR0315889A (https=)
CA (1) CA2504263A1 (https=)
MX (1) MXPA05004486A (https=)
NZ (1) NZ540185A (https=)
TW (1) TW200418455A (https=)
WO (1) WO2004041181A2 (https=)
ZA (1) ZA200503468B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402980A (zh) * 2011-01-10 2013-11-20 细胞基因公司 作为pde 4 和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
WO2020113373A1 (en) * 2018-12-03 2020-06-11 Zhuhai Qiwei Bio-Technology Ltd. Method of treating age-related macular degeneration
CN113226020A (zh) * 2018-11-14 2021-08-06 珠海岐微生物科技有限公司 用于眼内疾病或病症的动物模型、筛选方法和治疗方法
TWI889970B (zh) * 2021-06-24 2025-07-11 日商山陽色素股份有限公司 紅色顏料分散體

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR101908330B1 (ko) 2017-02-17 2018-10-16 인제대학교 산학협력단 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577589A (en) * 1897-02-23 Valve for explosive-engines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
CA2295295A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels
WO1999058096A2 (en) * 1998-05-11 1999-11-18 Entremed, Inc. Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
JP2000159761A (ja) * 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
EP1556033A4 (en) * 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
JP2006510606A (ja) * 2002-10-15 2006-03-30 セルジーン・コーポレーション 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402980A (zh) * 2011-01-10 2013-11-20 细胞基因公司 作为pde 4 和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
CN103402980B (zh) * 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
CN113226020A (zh) * 2018-11-14 2021-08-06 珠海岐微生物科技有限公司 用于眼内疾病或病症的动物模型、筛选方法和治疗方法
WO2020113373A1 (en) * 2018-12-03 2020-06-11 Zhuhai Qiwei Bio-Technology Ltd. Method of treating age-related macular degeneration
TWI889970B (zh) * 2021-06-24 2025-07-11 日商山陽色素股份有限公司 紅色顏料分散體

Also Published As

Publication number Publication date
JP2006509743A (ja) 2006-03-23
KR20050062649A (ko) 2005-06-23
EP1567148A4 (en) 2010-09-15
WO2004041181A3 (en) 2005-02-17
ZA200503468B (en) 2006-10-25
BR0315889A (pt) 2005-10-04
EP1567148A2 (en) 2005-08-31
MXPA05004486A (es) 2005-07-26
NZ540185A (en) 2008-01-31
AU2003285107A1 (en) 2004-06-07
WO2004041181A2 (en) 2004-05-21
AU2003285107B2 (en) 2008-01-10
TW200418455A (en) 2004-10-01
CA2504263A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
CN1886131A (zh) 用于治疗黄斑变性的组合物和方法
CN1213026C (zh) N－杂环化合物的羧酸和羧酸电子等排物
CN1313447C (zh) 用于降低眼内压的8－氮杂前列腺素类似物
CN1913896A (zh) 用于治疗和控制血红蛋白病和贫血病的方法和组合物
CN1921758A (zh) 治疗中枢神经系统疾病的免疫调节化合物
CN1668296A (zh) 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
CN1158073C (zh) 蛋白激酶c抑制剂在制备药物中的应用
CN1653125A (zh) 白内障和其它眼病发展的改善
CN1972684A (zh) 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
CN1713905A (zh) 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
CN1731998A (zh) 用于治疗、缓解和控制疼痛的包含选择性细胞因子抑制药物的组合物及使用方法
CN1731997A (zh) 使用包含选择性细胞因子抑制药物的组合物治疗和控制黄斑变性的方法
CN1732001A (zh) 治疗黄斑变性的组合物
US20110038832A1 (en) Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CN1780616A (zh) 治疗中枢神经系统疾病的选择性细胞因子抑制药物
HK1087933A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
CN1720226A (zh) 用于治疗和控制骨髓增生性疾病的选择性的细胞因子抑制药物的使用方法和包括其的组合物
AU2008201418B2 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
HK1098706A (en) Cytokine inhibitory drugs for treatment of macular degeneration
HK1093446A (en) Composition and method for treating macular degeneration
HK1087024A (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
HK1087934A (en) Composition for the treatment of macular degeneration
MXPA06004622A (en) Cytokine inhibitory drugs for treatment of macular degeneration
HK1088220A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1732003A (zh) 用于治疗、预防和控制黄斑变性的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087933

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20060208

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1087933

Country of ref document: HK